Skip to content
Omnikalc

APRI: AST to platelet ratio index for liver fibrosis

Calculate the APRI score from AST and platelet count to estimate the likelihood of significant liver fibrosis or cirrhosis.

Updated on
Your inputs
U/L

Value out of range

U/L

Value out of range

×10³/µL

Value out of range

Results

APRI score

1.33

0.5 to 1.5: indeterminate, further tests needed
AST as a multiple of the upper limit of normal
2.00 × ULN

A liver fibrosis estimate from routine blood tests

Chronic liver diseases, such as hepatitis B or C, fatty liver disease or long-term heavy drinking, slowly replace healthy liver tissue with scar tissue. This fibrosis can progress silently over decades to cirrhosis, which raises the risk of liver failure and liver cancer. Measuring fibrosis used to require a liver biopsy. In 2003, Chun-Tao Wai and colleagues at the University of Michigan proposed a simple alternative based on two tests almost every patient already has.

The formula

APRI = (AST ÷ upper limit of normal for AST) ÷ platelet count (×10³/µL) × 100

  • AST is a liver enzyme that rises as the liver is damaged.
  • Platelets fall as fibrosis advances, because scarring raises pressure in the portal vein, enlarges the spleen and traps platelets there.

Interpreting the score

APRI Interpretation
0.5 or less Significant fibrosis unlikely
0.5 to 1.5 Indeterminate
Above 1.5 Significant fibrosis likely
Above 2 Cirrhosis likely

Worked example

A patient has an AST of 80 U/L, with a laboratory upper limit of 40 U/L, and a platelet count of 150 ×10³/µL.

APRI = (80 ÷ 40) ÷ 150 × 100 = 1.33

The score falls in the indeterminate zone. Another test, such as FIB-4 or elastography, would be needed to classify the fibrosis.

Strengths and limits

  • Cheap and available everywhere, which is why the World Health Organization’s hepatitis guidelines recommend it for settings without elastography.
  • Many patients fall in the middle zone, where it cannot decide.
  • AST rises for other reasons, such as recent alcohol intake, muscle injury or acute hepatitis, which inflate the score.
  • Platelets fall for other reasons, such as some medications or bone marrow disorders.
  • It was developed in hepatitis C. It performs less well in fatty liver disease, where FIB-4 or the NAFLD fibrosis score are preferred.

Your hepatologist or primary care doctor interprets the score together with imaging and the rest of your results.

This calculator is for general information and education. It is not medical advice and does not replace the judgment of a doctor, nurse or pharmacist who knows the full clinical picture.

Frequently asked questions

What is the APRI score?

The AST to platelet ratio index: (AST ÷ upper limit of normal) ÷ platelet count × 100. It was proposed in 2003 by Wai and colleagues to estimate liver fibrosis in hepatitis C without a biopsy.

What do the cut-offs mean?

0.5 or less makes significant fibrosis unlikely. Above 1.5 suggests significant fibrosis, and above 2 suggests cirrhosis. Between 0.5 and 1.5, the score cannot decide and other tests are needed.

Why use the lab's upper limit of normal?

Normal ranges for AST differ between laboratories, typically 33 to 40 U/L. Dividing by the lab's own limit makes results comparable. The upper limit is printed on your lab report.

Is APRI as good as FibroScan?

No. APRI is cheap and uses routine blood tests, but it misses some patients with fibrosis. Elastography (FibroScan) or combined blood tests such as FIB-4 are more accurate, and the World Health Organization recommends APRI mainly where they are unavailable.

Was this calculator helpful?

Thanks for your feedback!

Results are estimates provided for information purposes. They do not replace professional advice.